Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.